reteplase

Reteplase
Clinical data
Trade names	Retavase
Drugs.com	monograph
Identifiers
CAS Number	133652-38-7
ATC code	B01AD07 (WHO)
DrugBank	DB00015
ChemSpider	none
UNII	DQA630RIE9
KEGG	D05721
Chemical data
Formula	C1736H2671N499O522S22
Molar mass	39589.6 g/mol
(verify)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/06/08 10:33:28」(JST)

wiki en

[Wiki en表示]

Reteplase (trade names Retavase, Rapilysin) is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.

Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.^{[citation needed]}

Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.

Reteplase was approved by the Food and Drug Administration in 1996.

As reteplase is able to penetrate inside the thrombi, an enhanced fibrinolytic activity will be achieved → rapid reperfusion → low incidence of bleeding.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ST上昇型心筋梗塞における血栓溶解療法の特性および臨床試験 characteristics of fibrinolytic thrombolytic agents and clinical trials in acute st elevation myocardial infarction
2. Fibrinolysis for acute ST elevation myocardial infarction: Initiation of therapy
3. ST上昇型心筋梗塞に対する血栓溶解後の経皮的冠動脈インターベンション percutaneous coronary intervention after fibrinolysis for acute st elevation myocardial infarction
4. 入院前の血栓溶解療法の効果 performance of prehospital fibrinolysis
5. 幼児および小児における静脈血栓症および血栓塞栓症の診断および治療 diagnosis and treatment of venous thrombosis and thromboembolism in infants and children

English Journal

Computational design, functional analysis and antigenic epitope estimation of a novel hybrid of 12 peptides of hirudin and reteplase.

Cai Y1, Bao J, Lao X, Zheng H, Chen J, Yu R.
Journal of molecular modeling.J Mol Model.2015 Sep;21(9):229. doi: 10.1007/s00894-015-2774-2. Epub 2015 Aug 13.
Cardiovascular and cerebrovascular diseases are leading causes of morbidity and mortality for human beings, and thrombosis is the major risk factor. Thrombolytic therapy has been testified to be the most effective approach to cure thrombosis-related diseases. In clinical treatment, we often adopt a
PMID 26267298

Stuck aortic valve treated by reteplase in a Bentall patient.

Tanyeli Ö1, Dereli Y, Düzenli MA, Görmüş N.
Anatolian journal of cardiology.Anatol J Cardiol.2015 Apr;15(4):339-40. doi: 10.5152/akd.2015.6024.
PMID 25880294

Approach to thrombotic occlusion related to long-term catheters of hemodialysis patients: a narrative review.

Mendes ML1, Barretti P1, da Silva TN1, Ponce D1.
Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia.J Bras Nefrol.2015 Apr-Jun;37(2):221-7. doi: 10.5935/0101-2800.20150035.
Currently, permanent catheters (pCVC) are becoming an alternative vascular access for long-stay patients in whom arteriovenous access cannot be made. Occlusion is a commun mechanical complication related to pCVC, leading to inadequate dialysis dose and frequent changes of local catheter location, wh
PMID 26154643

Japanese Journal

Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke : An open-label, dose-ranging phase I study

Neurosurgery 59, 789-797, 2006
NAID 30012793551

Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in actute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) trial.